Loading
Paediatric oncologist who chaired COG AALL0434, the largest trial ever run in childhood T-cell leukaemia, which showed that adding nelarabine improves disease-free survival.
Kimberly Dunsmore chaired the Children's Oncology Group trial AALL0434 in T-cell acute lymphoblastic leukaemia and lymphoma. She was first author of its 2020 Journal of Clinical Oncology report, which showed that adding nelarabine to augmented BFM chemotherapy improved disease-free survival in children and young adults with T-ALL, and that the regimen produced the best outcomes yet reported for the disease. She has held paediatric oncology leadership roles at the University of Virginia and Carilion Clinic.
| Title | Journal | Year |
|---|---|---|
| AALL0434: nelarabine in newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults | Journal of Clinical Oncology | 2020 |
Shares Childhood cancers (all types), Acute lymphoblastic leukaemia and the tags paediatric, leukaemia, trialist.
Shares Childhood cancers (all types), Acute lymphoblastic leukaemia and the tags paediatric, leukaemia, trialist.
Shares AALL0434: nelarabine in newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults, COG AALL0434, High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL), Acute lymphoblastic leukaemia.
Shares the tags leukaemia, trialist.
Shares the tags leukaemia, trialist.
Shares the tags leukaemia, trialist.
Shares Childhood cancers (all types) and the tags paediatric, trialist.
Shares Childhood cancers (all types) and the tags paediatric, trialist.